- Policy
- Meqsel+Rafinlar combination NSCLC indication reimbursed
- by Kim, Jung-Ju Feb 12, 2020 06:27am
- Korea’s top healthcare reimbursement decision-making body has passed listing of Yooyoung Pharmaceutical’s chronic constipation treatment Rucalo tablet (prucalopride succinate) and expanded reimbursement on Novartis Korea’s Meqsel (trametinib dimethyl sulfoxide) plus Rafinlar (dabrafenib mesylate) combination therapy. The revised List of Re
- Company
- JAK-inhibiting oral antirheumatic drug market getting fuller
- by Eo, Yun-Ho Feb 11, 2020 06:31am
- Orally taken antirheumatic treatment, JAK inhibitor drug market in Korea would be soon led by four competitors. According to pharmaceutical industry, the close competition between Pfizer’s Xeljanz (tofacitinib) and Lilly’s Olumiant (baricitinib) would get even intensified as Astellas Pharma’s Smyraf (peficitinib) entered the competit
- Opinion
- All the access in China must be cut off
- by Nho, Byung Chul Feb 11, 2020 06:30am
- 2019n-CoV is a RNA virus belonging to beta corona, similar to SARS or MERS, and is a common infectious disease with high mortality due to the absence of vaccines and treatments. The mortality rate of SARS and MERS was 10% and 30%, respectively. This is due to the level of medical care, and because it has very high gene homology with SARS and
- Product
- It costs ₩867 million to become a physician
- by Kang, Shin-Kook Feb 11, 2020 06:29am
- It is estimated that it costs &8361;867 million from entering medical school to obtaining professional qualification. The Korean Medical Association(KMA)'s research institute for healthcare policy (Director Deok-sun Ahn) announced on the 7th that it has published a research report on the estimation of doctor training costs and public support
- Company
- Pfizer recalling Lipitor and Caduet in defective packaging
- by Jung, Hye-Jin Feb 11, 2020 06:29am
- Pfizer Korea is recalling some of Lipitor and Caduet stocks, not because of the drug itself but because of defective packaging. On Feb. 6, Pfizer Korea disseminated official notice to vendors and requested them to suspend shipping of Lipitor and Caduet. The shipping is halted for Lipitor 10 mg in 90-tablet packaging with manufacturer
- Policy
- Strensiq, a rare disease treatment, passed the Committee
- by Lee, Hye-Kyung Feb 11, 2020 06:28am
- Strensiq, a rare disease treatment , passed the Pharmaceutical Benefits Advisory Committee On the 6th, the HIRA (Director Seung-taek Kim) revealed the results of the review by the Pharmaceutical Benefits Advisory Committee on the adequacy of the medical benefits of the drug application. Only one drug has been evaluated for adequacy of r
- Policy
- Phase 3 trial for Korea-made DPP-4 + SGLT-2 approved
- by Lee, Tak-Sun Feb 10, 2020 06:31am
- Apparently, Phase III clinical protocols of two new Korea-made anti-diabetic treatments based on DPP-4 inhibitor, Suganon (evoglitin by Dong-A ST) and Zemiglo (gemigliptin by LG Chem), have been approved to test their combination efficacy with SGLT-2 inhibitor drug. Among nine new dipeptidyl peptidase 4 (DPP-4) inhibitor drugs competing
- Product
- Lyxumia by Sanofi stops supply in the second half
- by Kim, Min-Gun Feb 10, 2020 06:31am
- Sanofi-Aventis Korea's supply of GLP-1 analog diabetes treatment ‘Lyxumia (Lixisenatide)’ will be discontinued from June this year. According to the distribution industry on the 7th, Sanofi recently announced that it has stopped supplying two formulations, such as 10μg and 20μg of Lyxumia pen, due to company circumstances. Sanofi sa
- Company
- MSD’s Spin off completes within this year
- by An, Kyung-Jin Feb 10, 2020 06:31am
- Employees of Korean subsidiaries had begun to stir as Merck (US MSD) declares a division of business. Anxiety over future behaviors is heightening as the company announces the launch of an independent corporation to manage women's health-related products, patent expired drugs, and biosimilars within the year. Decision to split MSD busines
- Company
- AstraZeneca, decided to withdrawal from the KDPU
- by Kim, Jin-Gu Feb 10, 2020 06:31am
- AstraZeneca Korea decided to withdraw from the KDPU(Korea Democratic Pharmaceutical Union). The branches of the KDPU have been reduced to 18, including 17 multinationals and 1 domestic. According to the pharmaceutical industry on the 6th, the Branch of AstraZeneca Korea under the KDPU has voted for members whether or not to withdraw from t
